About this Journal Submit a Manuscript Table of Contents
ISRN Urology
Volume 2013 (2013), Article ID 786545, 6 pages
http://dx.doi.org/10.1155/2013/786545
Research Article

ERG Protein Expression Is of Limited Prognostic Value in Men with Localized Prostate Cancer

1Department of Pathology and Laboratory Medicine, University of Calgary and Calgary Laboratory Services, Calgary, AB, Canada T2V 1P9
2Department of Urology, University of Calgary, Calgary, AB, Canada T2N 1N4
3The Prostate Cancer Center, Calgary, AB, Canada T2V 1P9
4Department of Oncology, Biochemistry and Molecular Biology, Calgary, AB, Canada T2N 1N4
5Southern Alberta Cancer Institute and Tom Baker Cancer Center, Calgary, AB, Canada T2N 1N4

Received 4 June 2013; Accepted 27 June 2013

Academic Editors: J. H. Ku, T. Nelius, and T. Nishiyama

Copyright © 2013 Liang Hong Teng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. J. van Leenders, J. L. Boormans, C. J. Vissers et al., “Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice,” Modern Pathology, vol. 24, no. 8, pp. 1128–1138, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. B. Furusato, S. H. Tan, D. Young et al., “ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification,” Prostate Cancer and Prostatic Diseases, vol. 13, no. 3, pp. 228–237, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. T. L. Lotan, N. S. Gupta, W. Wang et al., “ERG gene rearrangements are common in prostatic small cell carcinomas,” Modern Pathology, vol. 24, no. 6, pp. 820–828, 2011. View at Publisher · View at Google Scholar
  4. M. Miettinen, Z. F. Wang, A. Paetau et al., “ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma,” The American Journal of Surgical Pathology, vol. 35, no. 3, pp. 432–441, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Park, S. A. Tomlins, K. M. Mudaliar et al., “Antibody-based detection of ERG rearrangement-positive prostate cancer,” Neoplasia, vol. 12, no. 7, pp. 590–598, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Chaux, R. Albadine, A. Toubaji et al., “Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas,” The American Journal of Surgical Pathology, vol. 35, no. 7, pp. 1014–1020, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. S. A. Tomlins, D. R. Rhodes, S. Perner et al., “Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer,” Science, vol. 310, no. 5748, pp. 644–648, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. M. J. Soller, M. Isaksson, P. Elfving, W. Soller, R. Lundgren, and I. Panagopoulos, “Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer,” Genes Chromosomes and Cancer, vol. 45, no. 7, pp. 717–719, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. S. A. Tomlins, R. Mehra, D. R. Rhodes et al., “TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer,” Cancer Research, vol. 66, no. 7, pp. 3396–3400, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. B. E. Helgeson, S. A. Tomlins, N. Shah et al., “Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer,” Cancer Research, vol. 68, no. 1, pp. 73–80, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. K. G. Hermans, H. A. van der Korput, R. van Marion et al., “Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer,” Cancer Research, vol. 68, no. 18, pp. 7541–7549, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Perner, F. Demichelis, R. Beroukhim et al., “TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer,” Cancer Research, vol. 66, no. 17, pp. 8337–8341, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. W. Liu, C. M. Ewing, B. L. Chang et al., “Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers,” Genes Chromosomes and Cancer, vol. 46, no. 11, pp. 972–980, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. L. M. FitzGerald, I. Agalliu, K. Johnson et al., “Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer,” BMC Cancer, vol. 8, article 230, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Hessels, F. P. Smit, G. W. Verhaegh, J. A. Witjes, E. B. Cornel, and J. A. Schalken, “Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer,” Clinical Cancer Research, vol. 13, no. 17, pp. 5103–5108, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Demichelis, K. Fall, S. Perner et al., “TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort,” Oncogene, vol. 26, no. 31, pp. 4596–4599, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Liu, M. Yoshimoto, K. Trpkov et al., “Detection of ERG gene rearrangements and PTEN deletions in unsuspected prostate cancer of the transition zone,” Cancer Biology and Therapy, vol. 11, no. 6, pp. 562–566, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. T. L. Lotan, A. Toubaji, R. Albadine et al., “TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas,” Modern Pathology, vol. 22, no. 3, pp. 359–365, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. A. H. M. Reid, G. Attard, L. Ambroisine et al., “Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer,” The British Journal of Cancer, vol. 102, no. 4, pp. 678–684, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. R. K. Nam, L. Sugar, W. Yang et al., “Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer,” The British Journal of Cancer, vol. 97, no. 12, pp. 1690–1695, 2007.
  21. O. R. Saramäki, A. E. Harjula, P. M. Martikainen, R. L. Vessella, T. L. J. Tammela, and T. Visakorpi, “TMPRSS2.ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis,” Clinical Cancer Research, vol. 14, no. 11, pp. 3395–3400, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. A. D. Darnel, C. J. LaFargue, R. T. Vollmer, J. Corcos, and T. A. Bismar, “TMPRSS2-ERG fusion is frequently observed in gleason pattern 3 prostate cancer in a canadian cohort,” Cancer Biology and Therapy, vol. 8, no. 2, pp. 125–130, 2009. View at Scopus
  23. A. M. Hoogland, G. Jenster, W. M. van Weerden et al., “ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer,” Modern Pathology, vol. 25, no. 3, pp. 471–479, 2012. View at Publisher · View at Google Scholar
  24. S. Minner, M. Enodien, H. Sirma et al., “ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy,” Clinical Cancer Research, vol. 17, no. 18, pp. 5878–5888, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. T. A. Bismar, M. Dolph, L. H. Teng, S. Liu, and B. Donnelly, “ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality,” European Journal of Cancer, vol. 48, no. 4, pp. 538–546, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. A. D. Darnel, E. Behmoaram, R. T. Vollmer et al., “Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer,” Clinical Cancer Research, vol. 15, no. 4, pp. 1376–1383, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. F. Brimo, R. T. Vollmer, M. Friszt, J. Corcos, and T. A. Bismar, “Syndecan-1 expression in prostate cancer and its value as biomarker for disease progression,” The British Journal of Urology International, vol. 106, no. 3, pp. 418–423, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. J. I. Epstein, W. C. Allsbrook Jr., M. B. Amin et al., “The 2005 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma,” The American Journal of Surgical Pathology, vol. 29, no. 9, pp. 1228–1242, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Perner, J. Mosquera, F. Demichelis et al., “TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion,” The American Journal of Surgical Pathology, vol. 31, no. 6, pp. 882–888, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. O. R. Saramäki, A. E. Harjula, P. M. Martikainen, R. L. Vessella, T. L. J. Tammela, and T. Visakorpi, “TMPRSS2.ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis,” Clinical Cancer Research, vol. 14, no. 11, pp. 3395–3400, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Yoshimoto, A. M. Joshua, I. W. Cunha et al., “Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome,” Modern Pathology, vol. 21, no. 12, pp. 1451–1460, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Gopalan, M. A. Leversha, J. M. Satagopan et al., “Tmprss2-erg gene fusion is not associated with outcome in patients treated by prostatectomy,” Cancer Research, vol. 69, no. 4, pp. 1400–1406, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Attard, J. S. de Bono, J. Clark, and C. S. Cooper, “Studies of TMPRSS2-ERG gene fusions in diagnostic trans-rectal prostate biopsies,” Clinical Cancer Research, vol. 16, no. 4, p. 1340, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. B. Han, R. Mehra, R. J. Lonigro et al., “Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression,” Modern Pathology, vol. 22, no. 8, pp. 1083–1093, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. T. A. Bismar, M. Yoshimoto, R. T. Vollmer et al., “PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer,” The British Journal of Urology International, vol. 107, no. 3, pp. 477–485, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. K. G. Hermans, J. L. Boormans, D. Gasi et al., “Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer,” Clinical Cancer Research, vol. 15, no. 20, pp. 6398–6403, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. A. M. Hoogland, G. Jenster, W. M. van Weerden et al., “ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer,” Modern Pathology, vol. 25, no. 3, pp. 471–479, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. J. M. Mosquera, S. Perner, F. Demichelis et al., “Morphological features of TMPRSS2-ERG gene fusion prostate cancer,” Journal of Pathology, vol. 212, no. 1, pp. 91–101, 2007. View at Publisher · View at Google Scholar · View at Scopus